Lantern Pharma (LTRN), conferencia de resultados del 2T de 2026: menor pérdida operativa, LP-300 y Open Medicine AI
Conferencia de resultados del Q2 de 2026 de Lantern Pharma: la pérdida operativa se redujo un 25 % a 3,5 millones de dólares y el efectivo fue de 7,4 millones de dólares, mientras que LP-300 y Open Medicine AI avanzaron.
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 100 billion oncology-focused data points and a library of over 200+ advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.